Drug intelligence / Profile preview

lenrispodun

Development stage: Phase 2
Lead developer: Intra-Cellular Therapies
Modality: Small Molecules
Administration: Oral

Overview

Lenrispodun is a potent, selective, and orally bioavailable small molecule inhibitor of phosphodiesterase type 1 (PDE1), developed primarily for the treatment of Parkinson’s disease and heart failure. It acts by blocking the breakdown of cyclic nucleotides (cAMP and cGMP), leading to increased intracellular levels that modulate cellular signaling pathways. This mechanism offers potential benefits in neurological and cardiovascular diseases by improving motor function in Parkinson’s disease and enhancing cardiac contractility without inducing arrhythmias in heart failure patients. Lenrispodun has demonstrated favorable safety profiles in multiple Phase 1/2a clinical trials[1][5][6][8].

Brand names: lenrispodun
Other names: Lenrispodun phosphate

Targets

PDE1 (Phosphodiesterase 1)ADORA2B (Adenosine A2B receptor)

Beyond the preview

Go deeper on lenrispodun.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lenrispodun.